significant prognostic factor. Taking the comparison a little further, they state that their own data are in general agreement with the literature, since they at least observed a trend. A statistical explanation (type II error) is even proposed. In fact their conclusion is the same as that of a recent review on the subject , i.e. that SPF is a significant prognostic factor, worth pursuing, but that DNAploidy is not. This is certainly not the impression that the reader would get from the title and the abstract.
How can we now improve our understanding of the value of DNA flow cytometry in defining breast cancer prognosis? Technical aspects can certainly be proposed. It is striking that the data on 3H-thymidine labelling of surgical biopsies of breast cancer seem to be more homogeneous (Meyer, 1986; Hery et al., 1987; Tubiana et al., 1989; Silvestrini et al., 1989) . The mitotic index has also been successfully used for over 35 years, as part of histopathological grading (Bloom & Richardson, 1957) . Therefore, the proliferative activity of breast cancers appears to be an important biological determinant of outcome, but, from a methodological point of view, the best way to measure it still remains an unresolved question.
In a study, soon to be published, six experienced 'cytometrists' were asked to classify some 400 DNA histograms of breast cancers. The interesting conclusion of this work was that the prognostic significance of DNA ploidy was maximal for the histograms that were agreed on, whereas for those for which opinions diverged, the outcome was similar to that of the aneuploid group (Joensu et al., 1992) . The major role of subjective elements in the interpretation of DNA histograms may be an important limitation of DNA flow cytometry, and attempts to standardise this interpretation should be instituted prior to its routine use in clinical practice.
In the excellent 'evaluation guidelines' for prognostic factors, the technical aspects were adequately dealt with (McGuire, 1991) , but the ever expanding field of prognostic factors raises the general problem of their multiple intercorrelations, potentially generating confusion for their practical application. One of the aspects that is seldom tackled concerns the search for an explanation of their association with clinical outcome. Along these lines, it is indicative that the results of the largest cytogenic study published to date suggest the existence of a possible unique pathway of genetic evolution of breast cancers, involving unbalanced chromosome translocations, endoreduplication and further chromosome losses (Dutrillaux et al., 1991) . This was achieved by analysing the proportion of rearranged chromosomes against the modal number of chromosome counts. Most importantly, it was consequently shown that the loss of both oestrogen and progesterone receptors was more frequent as the karyotypes became more complex (Magdelenat et al., 1992) . A similar pattern has been confirmed for S-phase fraction (Remvikos et al., 1992) or histopathological grade (Zafrani & Dutrillaux, unpublished results) . Although at present the data are insufficient to discuss the chronology of the events, it can be hypothesised that a set of biological parameters (including S-phase fraction) correlate with the state of genetic evolution, a finding that could explain their potential prognostic value.
Finally, it must be stressed that S-phase fractions of breast cancer present the additional value of interaction with treatment. We have previously suggested the existence of a relationship between S-phase fraction and response to neoadjuvant chemotherapy (Remvikos et al., 1989) . This has been confirmed by different groups (Spyratos et al., 1992; . One can speculate that different therapeutic strategies could be developed, not only based on prognosis, but also designed to achieve improved efficacy against tumours with different proliferative characteristics, much in the same way as it has been proposed that accelerated fractionation radiotherapy should be used for fast growing tumours (Peters et al., 1988) .
In the light of these comments, the decision to publish or not to publish the negative results of the study by Stanton et al. appears to be a secondary point. Although it is claimed that it counterbalances some other overoptimistic studies, its contribution to our knowledge on breast cancer proliferation and its prognostic value is quite limited.
Yours etc, 
